Pegcetacoplan

Phase 3Active

0 views this week 0 watching💤 Quiet

Interest: 38/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

C3G

Conditions

C3G, IC-MPGN, C3 Glomerulopathy, C3 Glomerulonephritis, Complement 3 Glomerulopathy, Complement 3 Glomerulopathy (C3G), Complement 3 Glomerulonephritis, Dense Deposit Disease, DDD, Membranoproliferative Glomerulonephritis, Membranoproliferative Glomerulonephritis (MPGN), Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)

Trial Timeline

May 29, 2023 → Jul 1, 2027

NCT ID

NCT05809531

About Pegcetacoplan

Pegcetacoplan is a phase 3 stage product being developed by Apellis Pharmaceuticals for C3G. The current trial status is active. This product is registered under clinical trial identifier NCT05809531. Target conditions include C3G, IC-MPGN, C3 Glomerulopathy.

What happened to similar drugs?

0 of 2 similar drugs in C3G were approved

Approved (0) Terminated (0) Active (2)

🔄Placebo + iptacopanNovartisPhase 3

🔄PegcetacoplanApellis PharmaceuticalsPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (14)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04729062	Pre-clinical	Completed	—	—	C3G
NCT07020832	Phase 3	Recruiting	Feb 1, 2026	Aug 1, 2028	Delayed Graft Function
NCT06161584	Pre-clinical	Active	Sep 28, 2023	Jun 1, 2027	Geographic Atrophy
NCT05809531	Phase 3	Active	May 29, 2023	Jul 1, 2027	C3G
NCT05067127	Phase 3	Completed	Nov 12, 2021	Jan 14, 2025	C3G
NCT04572854	Phase 2	Active	Sep 7, 2021	Jan 1, 2026	C3G
NCT04901936	Phase 2	Recruiting	Feb 4, 2021	Dec 1, 2028	Paroxysmal Nocturnal Hemoglobinuria (PNH)
NCT03531255	Phase 3	Active	Aug 27, 2018	Jun 1, 2025	PNH
NCT03593200	Phase 2	Completed	Aug 16, 2018	Oct 22, 2019	PNH
NCT03465709	Phase 1/2	Terminated	Feb 14, 2018	Apr 5, 2019	Neovascular Age-related Macular Degeneration
NCT02588833	Phase 1	Completed	Dec 1, 2015	Aug 26, 2019	Paroxysmal Nocturnal Hemoglobinuria
NCT02503332	Phase 2	Completed	Sep 24, 2015	Jan 17, 2018	Geographic Atrophy
NCT02264639	Phase 1	Completed	Feb 23, 2015	Oct 22, 2018	Paroxysmal Nocturnal Hemoglobinuria (PNH)
NCT02461771	Phase 1	Completed	Jan 28, 2015	Mar 8, 2016	Neovascular Age-Related Macular Degeneration

Competing Products

6 competing products in C3G

See all competitors

Product	Company	Stage	Hype Score
Iptacopan	Novartis	Pre-clinical	30
Placebo + iptacopan	Novartis	Phase 3	47
Avacopan + Avacopan Matching Placebo	Amgen	Phase 2	35
Pegcetacoplan	Apellis Pharmaceuticals	Phase 2	33
Pegcetacoplan	Apellis Pharmaceuticals	Phase 3	34
Pegcetacoplan	Apellis Pharmaceuticals	Pre-clinical	20